E-viri
PDF
Recenzirano
Odprti dostop
-
Wang, Michael; Munoz, Javier; Goy, Andre; Locke, Frederick L; Jacobson, Caron A; Hill, Brian T; Timmerman, John M; Holmes, Houston; Jaglowski, Samantha; Flinn, Ian W; McSweeney, Peter A; Miklos, David B; Pagel, John M; Kersten, Marie-Jose; Milpied, Noel; Fung, Henry; Topp, Max S; Houot, Roch; Beitinjaneh, Amer; Peng, Weimin; Zheng, Lianqing; Rossi, John M; Jain, Rajul K; Rao, Arati V; Reagan, Patrick M
The New England journal of medicine, 04/2020, Letnik: 382, Številka: 14Journal Article
Patients with mantle-cell lymphoma who have a relapse after chemotherapy and anti-CD20 and BTK inhibitor therapy have a poor prognosis. An injection of CD19-directed CAR T cells induced a complete response in 59% of patients; 78% with a complete response were in remission at 1 year. About two thirds of patients had serious adverse events, a finding consistent with previous data.
